Recent Company News

• 09:04 AM ET May 12, 2026
  

  Astellas Pharma announces results from post hoc analysis of GATHER1 and GATHER2 pivotal studies of IZERVAY (¥2328.0000, 0)

• 07:09 AM ET Apr 27, 2026
  

  Transcript Intelligence: Astellas Pharma Q4 Earnings Guidance

• 07:08 AM ET Apr 27, 2026
  

  Transcript Intelligence: Astellas Pharma Q4 Earnings Themes

• 07:08 AM ET Apr 27, 2026
  

  Transcript Intelligence: Astellas Pharma Q4 Earnings Q&A

• 02:38 AM ET Apr 27, 2026
  

  Astellas Pharma reports Q4 core profit ¥92.8B vs FactSet ¥75.80B (¥2385.5000, 0)

• 06:52 AM ET Apr 20, 2026
  

  Merck announces FDA grants priority review for KEYTRUDA and KEYTRUDA QLEX, each with Padcev, for cisplatin-eligible patients with MIBC ($119.07, 0.00)

• 08:09 AM ET Apr 16, 2026
  

  Vir Biotechnology announces closing of strategic collaboration with Astellas ($10.46, 0.00)

• 11:50 PM ET Apr 14, 2026
  

  Astellas Pharma doses first patient in phase 3 study of combining ASP3082 with mFOLFIRINOX or NALIRIFOX for KRAS G12D-mutated PDAC

• 10:05 AM ET Apr 13, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 11-Apr

• 08:16 AM ET Apr 08, 2026
  

  Dyno Therapeutics (private) announces capsid license exercised by Astellas for skeletal muscle-targeted Gene delivery